1. Maehara Y, Okuyama T, Kakeji Y, Baba H, Furusawa M, Sugimachi K (1994) Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 168:36–40
2. Kim SY, Park HC, Yoon C, Yoon HJ, Choi YM, Cho KS (1998) OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized phase III trial. Cancer 83:2054–2059
3. Ikehara M, Oshita F, Suzuki R, Saitoh H, Yamada K, Noda K (2004) Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa. J Exp Ther Oncol 4:79–83
4. Kai S, Tanaka J, Nomoto K, Torisu M (1979) Studies on the immunopotentiating effects of a streptococcal preparation, OK-432. I. Enhancement of T cell-mediated immune responses of mice. Clin Exp Immunol 37:98–105
5. Oshimi K, Kano S, Takaku F, Okumura K (1980) Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Natl Cancer Inst 65:1265–1269